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Abstract
Background: Ganoderic acid B is an important bioactive ingredient isolated from Ganoderma lucidum, and exhibits vari-
ous pharmacological activities.
Aims: To investigate the influence of  Ganoderic acid B towards the therapeutic window of  trifluoperazine (TFP).
Methods: In vitro human liver microsomes (HLMs) incubation system was used to determine the inhibition of   Ganoderic 
acid B towards the glucuronidation of  trifluoperazine (TFP).
Results: Ganoderic acid B exerted concentration-dependent inhibition towards the glucuronidation of  TFP. Furthermore, 
Dixon plot was used to determine the inhibition type. The intersection point was located in the second quadrant in Dixon 
plot, indicating the competitive inhibition of  Ganoderic acid B towards TFP glucuronidation. Through fitting the data using 
competitive nonlinear fitting equation, the inhibition kinetic parameter was calculated to be 56.7 uM. 
Conclusion:  All this data indicated the potential influence of  Ganoderic acid B-containing herbs towards therapeutic win-
dow of  TFP. Given that the glucuronidation reaction of  TFP is the probe reaction of  UGT1A4, the data obtained from the 
present study also indicated the potential influence of  Ganoderic acid-containing herbs towards the therapeutic window of  
drugs mainly undergoing UGT1A4-mediated metabolism. 
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Ganoderma lucidum, a well-known traditional Chinese 
medicine, has been utilized for longevity and treatment 
of  multiple diseases in Asia for many years1. Ganoder-
ic acids, the oxygenated lanostane-type triterpenoids 
isolated from Ganoderma lucidum, have been report-
ed to exhibit multiple biochemical and pharmacolog-
ical activities, such as anti-tumor2,3, cardioprotective 
and liver protection activity4,5. The development of  
the compounds needs the adverse effects and in vivo 
elimination information, besides the pharmacologically 
therapeutic role.
Metabolic enzymes-catalyzed biotransformation pro-
cess has been considered to be an important cause for 
the adverse effects of  drugs. For example, cytochrome 
P450 (CYP) 2E1-mediated metabolic activation of  
acetaminophen has been regarded as the major reason 
for acetaminophen-induced acute liver failure6. Addi-
tionally, the inhibition of  compounds towards the ac-
tivity of  drug-metabolizing enzymes (DMEs) is another 
reason for drugs-induced adverse effects. For example, 
the anti-tumor drug noscapine exhibits significant in-
hibitory effects towards CYP3A4 and CYP2C9-cata-
lyzed warfarin metabolism, and then induces clinical 
noscapine-warfarin interaction7. For one of  the most 
important phase II DMEs UDP- glucuronosyltrans-
ferases (UGTs), the activity inhibition will also induce 
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the severe adverse effects. For example, HIV therapeu-
tic drug indinavir inhibited UGT1A1-mediated biliru-
bin glucuronidation to induce the elevation of  uncon-
jugated bilirubin8.
Trifluoperazine (TFP) is a typical antipsychotic of  the 
phenothiazine chemical class, and its major clinical ap-
plication is to treat schizophrenia9. The adverse effects 
of  TFP contain extrapyramidal reactions (e.g., Parkin-
son-like symptoms, dystonia, etc.), drowsiness, fatigue, 
muscular weakness, and hypotension.
According to the reports from Drugs.com website, a 
total of  1056 drugs can induce the drug-drug interac-
tion (DDI) with TFP. TFP has relatively narrow thera-
peutic window, and major drug-metabolizing enzyme to 
contribute to the metabolism of  TFP is UGT1A4. The 
present study aims to investigate the inhibition of  Gan-
oderic Acid B towards the metabolism of  TFP.
Materials and Methods
Chemicals and Reagents
Tris-HCl, 7-hydroxycoumarin, and uridine-5-diphos-
phoglucuronic acid (UDPGA) (trisodium salt) were 
obtained from Sigma-Aldrich (St. Louis, MO). Sig-
ma-Aldrich also offers the trifluoperazine dihydrochlo-
ride for the research needs. Pooled human liver micro-
somes (HLMs) were prepared according to previous 
reports10,11.
Ganoderic Acid B’s inhibition towards the glucuro-
nidation of  TFP 
The formation of  TFP glucuronide and the chroma-
tography conditions were carried out as previously de-
scribed12. In brief, the incubation system (200 uL) con-
tains 50 mM Tris-HCl (pH=7.4), 25 ug/mL lamethicin 
(from Trichoderma viride), 0.1 mg/ml HLMs, 5 mM 
MgCl2, 5 mM UDPGA, and various concentrations 
of  TFP and Gaboderic Acid B. The incubation time 
was 20 min, and the incubation temperature was 370C. 
The incubation conditions ensure the linear reaction of  
TFP glucuronidation. The reaction was terminated with 
the equal volume of  methanol, and the aliquots (10 uL)
were used for analysis. The inhibition kinetic type was 
determined through Dixon plot (Reaction velocity ver-
sus the concentrations of  Ganoderic acid B), and the 
inhibition kinetic parameters were calculated using the 
nonlinear regression equations as followed according 
to previous literatures13-15. V=(VmaxS)/(Km(1+I/
Ki)+S) (1) V=(VmaxS)/(Km+S) (1+I/Ki) (2)
The equations (1) and (2) were employed for competi-
tive and noncompetitive fitting, respectively. The terms 
in the equations were defined as followed: V is the ve-
locity, S is the concentration of  substrate, Km is the 
metabolism kinetic parameter, I is the concentration of  




Multiple concentrations of  Ganoderic acid B were used 
to screen the inhibition potential of  Ganoderic acid B 
towards TFP glucuronidation, and the results showed 
that 0, 20, 40, 60 and 100 uM of  Ganoderic acid B in-
hibited the glucuronidation activity of  TFP by 0, 26.6%, 
44.1%, 52.9%, and 66.9%, respectively (Fig. 1). 
Fig. 1 Concentration-dependent inhibition of  Ganoder-
ic Acid B towards the glucuronidation of  trifluopera-
zine (TFP). The residul percentage of  control activity 
was employed to represent the inhibition capability of  
Ganoderic acid B towards the glucuronidation activi-
ty of  TFP. Two replicate experiments were carried out, 
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Furthermore, the Dixon plot using the 1/reaction ve-
locity versus the concentrations of  Ganoderic acid B 
was drawn to determine the inhibition kinetic type, and 
the intersection point was located into the second quad-
rant, indicating the competitive inhibition type (Fig. 2). 
Through fitting the data using competitive nonlinear 
fitting equation, the inhibition kinetic parameter (Ki) 
was calculated to be 56.7 uM.
Fig. 2 Determination of  inhibition kinetic type using 
the Dixon plot. The Dixon plot used the reaction ve-
locity versus the concentrations of  Ganoderic acid B. 













In vitro incubation system is an useful tool to inves-
tigate the metabolic behavior of  xenobiotics and me-
tabolism-mediated adverse effects. Through adding dif-
ferent co-factors, the phase I and phase II metabolic 
pathways can be well separated, and the inhibition be-
havior towards the metabolism can be studied through 
co-incubation with another compound. The present 
study investigated the inhibition potential of  Ganoderic 
acid B towards TFP glucuronidation, and the competi-
tive inhibition of  Ganoderic acid B was demonstrated, 
indicating the utilization risk when co-administration of  
Ganoderic acid B-containing herbs and TFP. Previous 
literatures have shown that other herbal components 
also exhibited inhibitory effects towards the glucuroni-
dation of  TFP16. Therefore, much attention should be 
paid to the clinical co-utilization of  TFP and Ganoderic 
acid B-containing herbs.
 
It should be noted that the glucuronidation reaction 
of  TFP has been widely employed as the probe reac-
tion of  UGT1A4. Many endogenous and xenobiotic 
compounds have been demonstrated to be the good 
substrates of  UGT1A4. For example, UGT1A4 can 
conjugate 25-hydroxyvitamin D3 (25OHD3) which is a 
clinical biomarker for assessment of  vitamin D status17. 
UGT1A4 majorly contributed to the glucuronidation 
of  tacrolimus which is a potent immunosuppressant18. 
UGT1A4 also catalyzed the metabolic elimination of  
primary, secondary, and tertiary amines, carcinogenic 
aromatic amines (β-naphthylamine, 4- aminobiphenyl, 
and benzidine), androgens, progestins, and plant ster-
oids (hecogenin, diosgenin, and tigogenin)19,20. When 
Ganoderic acid B-containing herbs were co-adminis-
tered with these drugs, the potential influence towards 
the therapeutic window of  these drugs might occur. 
 
Conclusion  
The  potential influence of  Ganoderic acid B-contain-
ing herbs towards the therapeutic window of  trifluop-
erazine (TFP) was reported in the present study, as in-
dicated by the in vitro inhibition of  Ganoderic acid B 
towards the glucuronidation of  TFP. Additionally, many 
compounds with similar structures with Ganoderic acid 
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B are speculated to be the inhibitors of  TFP glucuroni-
dation, and will be investigated in the future.
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